Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome.
Cabral WA, Tavarez UL, Beeram I, Yeritsyan D, Boku YD, Eckhaus MA, Nazarian A, Erdos MR, Collins FS.
Aging Cell. 2021 Aug 28:e13457. doi: 10.1111/acel.13457.
In the paper, the authors report the phenotype of mice bred to carry two copies of the human BAC harbouring the common mutation G608G in the LMNA gene, which more completely recapitulate the phenotypic features of Hutchinson-Gilford progeria Syndrome (HGPS) in skin, adipose, skeletal, and vascular tissues. They further show that genetic reduction of the mechanistic target of rapamycin (mTOR) significantly extends lifespan in these mice, providing a rationale for pharmacologic inhibition of the mTOR pathway in the treatment of HGPS.
Medline link: https://pubmed.ncbi.nlm.nih.gov/34453483/